Tag Archives: Sam Slutsky

BELLUS Health (BLU) Gets a Buy Rating from LifeSci Capital

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on BELLUS Health (BLU – Research Report) on August 4 and set a price target of $9.00. The company’s shares closed last Friday at $5.99. According to TipRanks.com, Slutsky is a

Analysts Are Bullish on Top Healthcare Stocks: BELLUS Health (BLU), Eli Lilly & Co (LLY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BELLUS Health (BLU – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments. BELLUS Health (BLU) In

LifeSci Capital Gives a Buy Rating to Catalyst Biosciences (CBIO)

In a report issued on March 4, Sam Slutsky from LifeSci Capital assigned a Buy rating to Catalyst Biosciences (CBIO – Research Report), with a price target of $16.00. The company’s shares closed last Thursday at $6.19. According to TipRanks.com,

InflaRx (IFRX) Gets a Hold Rating from LifeSci Capital

LifeSci Capital analyst Sam Slutsky maintained a Hold rating on InflaRx (IFRX – Research Report) on January 13 and set a price target of $7.00. The company’s shares closed last Tuesday at $5.90. According to TipRanks.com, Slutsky is a 4-star

LifeSci Capital Keeps Their Buy Rating on Celldex (CLDX)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex (CLDX – Research Report) on December 8 and set a price target of $32.00. The company’s shares closed last Friday at $17.42. According to TipRanks.com, Slutsky is a 4-star

LifeSci Capital Believes Celldex (NASDAQ: CLDX) Still Has Room to Grow

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex (CLDX – Research Report), with a price target of $32.00. The company’s shares closed last Tuesday at $22.25, close to its 52-week high of